Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
July 25, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
July 24, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma
July 14, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)
July 10, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
July 05, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
June 15, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
MEIP
Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research
April 13, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Reports Full Year 2022 Financial Results
March 28, 2023
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib
November 14, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
November 07, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
August 31, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
August 02, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
May 17, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
May 03, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast
April 26, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights
March 29, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
March 22, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference
January 20, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
January 05, 2022
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index
December 14, 2021
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat
December 13, 2021
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium
December 10, 2021
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium
December 06, 2021
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
November 02, 2021
From
Infinity Pharmaceuticals, Inc.
Via
Business Wire
Tickers
INFI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.